Biologics Battle Over Billions of Dollars

Fight Fueled by FTC Report That Says 12-Year Exclusivity Unnecessary

By Kate Ackley
Roll Call Staff

June 15, 2009, 12 a.m.

Lobbyists who want Congress to approve a swift pathway to generic versions of biotech drugs say the Federal Trade Commission last week handed their side a boost just as Congress wades into the health care reform debate.

Most Popular
Most E-Mailed

Democrats Confident as Marathon Saturday Session Begins
Landrieu to Vote to Begin Debate
CRS Report Shows Most Bills Subject to Cloture Pass

Senate Phones Disrupted by Deluge of Calls
Lugar’s Wife Arrested for DUI

Committee
Insider
Policy
Briefings
Mission
Ahead
10 Staffers
to Know

Schumer Advocates for Many on Panel

Nov. 16, 12 a.m.

As Senate Majority Leader, Lyndon Johnson once said of the Joint Economic Committee, “It’s as useless as tits on a bull.” But as that panel’s chairman during the 110th Congress, Sen. Charles Schumer (D-N.Y.) seized the opportunity to elevate the traditionally low-profile post to the forefront of shaping policy. Read Full Article